Viking Therapeutics Shares Plummet Following Clinical Trial Data Release

Shares of Viking Therapeutics experienced a dramatic sell-off after the biopharmaceutical company released Phase 2 trial results for its oral weight-loss drug candidate, VK2735. The stock plummeted approximately 34% as investors digested the complex data set.

While the study demonstrated impressive efficacy—with the highest dose group achieving an average weight reduction of 12.2% in just 13 weeks—concerns over patient discontinuation rates and gastrointestinal side effects overshadowed these positive results. This adverse reaction prompted a significant market reassessment of the drug’s commercial potential.

Key Trial Outcomes and Market Context

Market experts noted that the speed of weight loss observed with VK2735 is notable, especially when compared to the timeframes required for competing therapies to achieve similar results. The company suggested that optimizing dosage levels Read more...